Abstract
A variety of compounds containing an imidazoline ring have the ability to stimulate insulin secretion. Many of these also improve glycaemia in experimental models of type 2 diabetes and in man, suggesting that this class may be useful in the development of new orally active anti-diabetic drugs. However, the mechanisms by which imidazolines promote insulin secretion have not been clarified. The response does not appear to be due to the binding of ligands to either of the two major types of imidazoline receptor defined by pharmacological criteria (I1 and I2 sites) but may result from interaction with a novel imidazoline binding site. One such site has been identified in association with the ATP-sensitive potassium (KATP ) channel in the beta-cell and has been designated I3 . Electrophysiological and biochemical evidence suggest that the I 3 site may be intrinsic to the ion-conducting pore component, Kir6.2, of the KATP channel, but the effects of imidazoline ligands on insulin secretion can be dissociated from the regulation of Kir6.2. Indeed, there is increasing evidence that some imidazolines can control exocytosis directly, both in b-cells and in pancreatic alpha-cells. Thus, it is proposed that a further imidazoline binding site is primarily responsible for control of hormone secretion. Evidence is reviewed which suggests that this site occupies a central position within an amplification pathway that also mediates the effects of cAMP in the beta-cell. Characterisation of this site should provide the stimulus for the design of new insulin secretagogues that are devoid of KATP channel-blocking properties.
Keywords: Imidazoline binding, insulin secretagogues, glycaemia, diabetes, midazoline receptor, efarozan, moxonidine, phentolamine, harmane, rilmenidine, Imidazoline binding proteins
Current Pharmaceutical Design
Title: Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?
Volume: 7 Issue: 14
Author(s): Noel G. Morgan and Sue L.F. Chan
Affiliation:
Keywords: Imidazoline binding, insulin secretagogues, glycaemia, diabetes, midazoline receptor, efarozan, moxonidine, phentolamine, harmane, rilmenidine, Imidazoline binding proteins
Abstract: A variety of compounds containing an imidazoline ring have the ability to stimulate insulin secretion. Many of these also improve glycaemia in experimental models of type 2 diabetes and in man, suggesting that this class may be useful in the development of new orally active anti-diabetic drugs. However, the mechanisms by which imidazolines promote insulin secretion have not been clarified. The response does not appear to be due to the binding of ligands to either of the two major types of imidazoline receptor defined by pharmacological criteria (I1 and I2 sites) but may result from interaction with a novel imidazoline binding site. One such site has been identified in association with the ATP-sensitive potassium (KATP ) channel in the beta-cell and has been designated I3 . Electrophysiological and biochemical evidence suggest that the I 3 site may be intrinsic to the ion-conducting pore component, Kir6.2, of the KATP channel, but the effects of imidazoline ligands on insulin secretion can be dissociated from the regulation of Kir6.2. Indeed, there is increasing evidence that some imidazolines can control exocytosis directly, both in b-cells and in pancreatic alpha-cells. Thus, it is proposed that a further imidazoline binding site is primarily responsible for control of hormone secretion. Evidence is reviewed which suggests that this site occupies a central position within an amplification pathway that also mediates the effects of cAMP in the beta-cell. Characterisation of this site should provide the stimulus for the design of new insulin secretagogues that are devoid of KATP channel-blocking properties.
Export Options
About this article
Cite this article as:
Morgan G. Noel and Chan L.F. Sue, Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?, Current Pharmaceutical Design 2001; 7 (14) . https://dx.doi.org/10.2174/1381612013397366
DOI https://dx.doi.org/10.2174/1381612013397366 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension
Current Hypertension Reviews The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Advancing Metabolomics Research and Biomarker Application with Nanotechnology
Current Metabolomics Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry <sup>1</sup>H NMR-Linked Urinary Metabolic Profiling of Niemann-Pick Class C1 (NPC1) Disease: Identification of Potential New Biomarkers using Correlated Component Regression (CCR) and Genetic Algorithm (GA) Analysis Strategies
Current Metabolomics Gut Microbiota as a Therapeutic Target for Metabolic Disorders
Current Medicinal Chemistry Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry New Insulin-Mimetic and Hypoglycemic Hetero-Binuclear Zinc(II)/ Oxovanadium(IV) Complex
Current Inorganic Chemistry (Discontinued) Editorial [Hot Topic: GPR30/GPER vs. ERalpha and ERbeta: Why Estrogens Need so Many Receptors (Guest Editor: Marcello Maggiolini)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not A
Current Vascular Pharmacology Psychotropics and Methadone in Acquired Long QT Syndrome
Current Psychopharmacology Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Pathology Among Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis
Current Diabetes Reviews Thyrotoxic Periodic Paralysis: A Concise Review of the Literature
Current Rheumatology Reviews The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews Foods versus Drugs for Health Promotion: Considerations for Future Directions
Current Pediatric Reviews